Acute Lymphocytic Leukemia

Clofarabine's interim results in leukemia reported at symposium

Published in Cancer Weekly, April 19th, 2005

Bioenvision (BIVN) announced interim results from the ongoing clinical studies of clofarabine in pediatric and adult acute leukemia trials which, the company states, confirm clofarabine's outstanding profile observed in previous studies.

Clofarabine has recently been approved by the U.S. Food and Drug Administration (FDA) in the U.S. for the treatment of relapsed/refractory pediatric acute lymphocytic leukemia (ALL).

Professors Alan K. Burnett and Varsha Ghandhi presented data from clofarabine's ongoing clinical development program at the sixth International Symposium and Expert Workshops on Leukemia and Lymphoma in Amsterdam, Netherlands, March...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry